Abstract Topics
Click the Theme names below to expand a full list of available topics.
Theme A: β-Amyloid Diseases
| A1.a. Disease Mechanisms, Pathophysiology: Abeta aggregation, protein misfolding |
| A1.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like |
| A1.c. Disease Mechanisms, Pathophysiology: Inflammation |
| A1.d. Disease Mechanisms, Pathophysiology: Synaptic plastcity & synapse pathology |
| A1.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium |
| A1.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress, chaperones |
| A1.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage |
| A1.h. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking |
| A1.i. Disease Mechanisms, Pathophysiology: Microglia |
| A1.j. Disease Mechanisms, Pathophysiology: Astroglia |
| A1.k. Disease Mechanisms, Pathophysiology: Neurogenesis |
| A1.l. Disease Mechanisms, Pathophysiology: Vasculature, microbleeds, hypertension, angiogenesis |
| A1.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier |
| A1.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin |
| A1.o. Disease Mechanisms, Pathophysiology: Neural networks, plasticity |
| A1.p. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs |
| A1.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death |
| A1.r. Disease Mechanisms, Pathophysiology: Aging |
| A1.s. Disease Mechanisms, Pathophysiology: Microbiome |
| A1.t. Disease Mechanisms, Pathophysiology: Other |
| A2.a. Therapeutic Targets, Mechanisms for Treatment: Abeta, truncated & pGlu-Abeta |
| A2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy |
| A2.c. Therapeutic Targets, Mechanisms for Treatment: Secretases, proteases |
| A2.d. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes |
| A2.e. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based |
| A2.f. Therapeutic Targets, Mechanisms for Treatment: ApoE & lipoprotein-based |
| A2.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory |
| A2.h. Therapeutic Targets, Mechanisms for Treatment: Anti-oxidants |
| A2.i. Therapeutic Targets, Mechanisms for Treatment: Neurotrophic, synaptic plasticity, repair, regenerative medicine |
| A2.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones |
| A2.k. Therapeutic Targets, Mechanisms for Treatment: TREM2 |
| A2.l. Therapeutic Targets, Mechanisms for Treatment: CD33 |
| A2.m. Therapeutic Targets, Mechanisms for Treatment: Microglia |
| A2.n. Therapeutic Targets, Mechanisms for Treatment: Astroglia |
| A2.o. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing |
| A2.p. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi |
| A2.q. Therapeutic Targets, Mechanisms for Treatment: neurogenesis and iPSC and brain organoids |
| A2.r. Therapeutic Targets, Mechanisms for Treatment: Other |
| A3.a. Drug Development, Clinical Trials: Immunotherapy |
| A3.b. Drug Development, Clinical Trials: Immunomodulators |
| A3.c. Drug Development, Clinical Trials: Amyloid clearance |
| A3.d. Drug Development, Clinical Trials: Secretase inhibitors & modulators |
| A3.e. Drug Development, Clinical Trials: Aggregation inhibitors |
| A3.f. Drug Development, Clinical Trials: Neuroprotective & mitochondrial compounds |
| A3.g. Drug Development, Clinical Trials: Neurotransmitter-based modulators |
| A3.h. Drug Development, Clinical Trials: Receptor ligands |
| A3.i. Drug Development, Clinical Trials: Mitochondrial drugs |
| A3.j. Drug Development, Clinical Trials: Cell-based therapies |
| A3.k. Drug Development, Clinical Trials: Transcranial magnetic stimulation |
| A3.l. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing |
| A3.m. Drug Development, Clinical Trials: Personalized medicines |
| A3.n. Drug Development, Clinical Trials: Regulatory aspects |
| A3.o. Drug Development, Clinical Trials:New clinical trial designs; Simulation of progress-digital twins |
| A3.p. Drug Development, Clinical Trials: Non-pharmacological interventions |
| A3.q. Drug Development, Clinical Trials: Other |
| A4.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy |
| A4.b. Imaging, Biomarkers, Diagnostics: Functional MRI |
| A4.c. Imaging, Biomarkers, Diagnostics: PET – amyloid |
| A4.d. Imaging, Biomarkers, Diagnostics: PET – glucose |
| A4.e. Imaging, Biomarkers, Diagnostics: PET – other |
| A4.f. Imaging, Biomarkers, Diagnostics: SPECT |
| A4.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging |
| A4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers |
| A4.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG |
| A4.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests, Digital endpoints, remote testing |
| A4.k. Imaging, Biomarkers, Diagnostics: Other |
| A5.a. Genetics, Epidemiology: Whole genome sequencing |
| A5.b. Genetics, Epidemiology: Disease-causing mutations |
| A5.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes |
| A5.e. Genetics, Epidemiology: Aging |
| A5.f. Genetics, Epidemiology: Environmental risk factors |
| A5.g. Genetics, Epidemiology: Metabolic and cardiovascular |
| A5.h. Genetics, Epidemiology: Infectious and inflammation |
| A5.i. Genetics, Epidemiology: Other |
| A6.a. Cell, Molecular and Systems Biology: APP, APLP, Abeta |
| A6.b. Cell, Molecular and Systems Biology: ApoE |
| A6.c. Cell, Molecular and Systems Biology: Secretases |
| A6.d. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity |
| A6.e. Cell, Molecular and Systems Biology: GCPR, nicotinic, sigma-1 & other receptors |
| A6.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations |
| A6.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics |
| A6.h. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation |
| A6.i. Cell, Molecular and Systems Biology: Other |
| A7.a. Animal Models: Transgenic rodents |
| A7.b. Animal Models: Primates, naturally occuring models and brain organoids |
| A7.c. Animal Models: Non-mamalian models |
| A7.d. Animal Models: Optogenetics |
| A7.e. Animal Models: Other |
Theme B: Taupathies
| B1.a. Disease Mechanisms, Pathophysiology: Tau aggregation, phophorylation, acetylation & modifications |
| B1.b. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like |
| B1.c. Disease Mechanisms, Pathophysiology: Inflammation |
| B1.d. Disease Mechanisms, Pathophysiology: Synapse pathology |
| B1.e. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium |
| B1.f. Disease Mechanisms, Pathophysiology: Lysosomes, ubiquitin, proteasome, ER stress |
| B1.g. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage |
| B1.h. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking |
| B1.i. Disease Mechanisms, Pathophysiology: Microglia |
| B1.j. Disease Mechanisms, Pathophysiology: Astroglia |
| B1.k. Disease Mechanisms, Pathophysiology: Neurogenesis |
| B1.l. Disease Mechanisms, Pathophysiology: Vasculature, angiogenesis |
| B1.m. Disease Mechanisms, Pathophysiology: Blood-brain barrier |
| B1.n. Disease Mechanisms, Pathophysiology: Metabolism, insulin |
| B1.o. Disease Mechanisms, Pathophysiology: Neural networks & plasticity |
| B1.p. Disease Mechanisms, Pathophysiology: transcriptional & translational regulation, micro RNAs |
| B1.q. Disease Mechanisms, Pathophysiology: Autophagy, apoptosis, cell death |
| B1.r. Disease Mechanisms, Pathophysiology: Protein misfolding, chaperones |
| B1.s. Disease Mechanisms, Pathophysiology: Aging |
| B1.t. Disease Mechanisms, Pathophysiology: Microbiome |
| B1.u. Disease Mechanisms, Pathophysiology: Other |
| B2.a. Therapeutic Targets, Mechanisms for Treatment: Tau, phosphorylation, truncation |
| B2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy |
| B2.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, phosphatases, other enzymes |
| B2.d. Therapeutic Targets, Mechanisms for Treatment: Neurotransmitters & receptor-based |
| B2.e. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory |
| B2.f. Therapeutic Targets, Mechanisms for Treatment: Anti-oxidants |
| B2.g. Therapeutic Targets, Mechanisms for Treatment: Neurotrophic, synaptic plasticity, repair |
| B2.h. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, NFT, misfolding, chaperones |
| B2.i. Therapeutic Targets, Mechanisms for Treatment: Gene and RNAi therapy |
| B2.j. Therapeutic Targets, Mechanisms for Treatment: Microglia |
| b2.k. Therapeutic Targets, Mechanisms for Treatment: Astroglia |
| B2.l. Therapeutic Targets, Mechanisms for Treatment: Adult neurogenesis |
| B2.m. Therapeutic Targets, Mechanisms for Treatment: Other |
| B3.a. Drug Development, Clinical Trials: Immunotherapy |
| B3.b. Drug Development, Clinical Trials: Immunomodulators |
| B3.c. Drug Development, Clinical Trials: tau clearance |
| B3.d. Drug Development, Clinical Trials: Kinase inhibitors & phosphatase modulators |
| B3.e. Drug Development, Clinical Trials: Aggregation inhibitors |
| B3.f. Drug Development, Clinical Trials: Neuroprotective & mitochondrial compounds |
| B3.g. Drug Development, Clinical Trials: Neurotransmitter-based modulators |
| B3.h. Drug Development, Clinical Trials: Mitochondrial drugs |
| B3.i. Drug Development, Clinical Trials: Cell-based therapies |
| B3.j. Drug Development, Clinical Trials: Transcranial magnetic stimulation |
| B3.k. Drug Development, Clinical Trials: Personalized medicines |
| B3.l. Drug Development, Clinical Trials: Regulatory aspects |
| B3.m. Drug Development, Clinical Trials:New clinical trial designs; Simulation of progress-digital twins |
| B3.n. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing |
| B3.o. Drug Development, Clinical Trials: Non-pharmacological interventions |
| B3.q. Drug Development, Clinical Trials: Other |
| B4.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy |
| B4.b. Imaging, Biomarkers, Diagnostics: Functional MRI |
| B4.c. Imaging, Biomarkers, Diagnostics: PET – tau |
| B4.d. Imaging, Biomarkers, Diagnostics: PET – glucose |
| B4.e. Imaging, Biomarkers, Diagnostics: PET – other |
| B4.f. Imaging, Biomarkers, Diagnostics: SPECT |
| B4.g. Imaging, Biomarkers, Diagnostics: Multimodal imaging |
| B4.h. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers |
| B4.i. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG |
| B4.j. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric & behavioral tests, Digital endpoints, remote testing |
| B4.k. Imaging, Biomarkers, Diagnostics: Other |
| B5.a. Genetics, Epidemiology: Whole genome sequencing |
| B5.b. Genetics, Epidemiology: Disease-causing mutations |
| B5.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes |
| B5.d. Genetics, Epidemiology: Aging |
| B5.e. Genetics, Epidemiology: Environmental risk factors |
| B5.f. Genetics, Epidemiology: Metabolic, cardiovascular, inflammation |
| B5.g. Genetics, Epidemiology: Other |
| B6.a. Cell, Molecular and Systems Biology: Tau, tau isoforms |
| B6.b. Cell, Molecular and Systems Biology: Kinases, phosphatases |
| B6.c. Cell, Molecular and Systems Biology: Posttranslational modifications |
| B6.d. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity |
| B6.e. Cell, Molecular and Systems Biology: GCPR, nicotinic, sigma-1, other receptors |
| B6.f. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations |
| B6.g. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics |
| B6.h. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation |
| B4.k. Cell, Molecular and Systems Biology: Other |
| B7.a. Animal Models: Transgenic rodents |
| B7.b. Animal Models: Primates, naturally occuring models and brain organoids |
| B7.c. Animal Models: Non-mamalian models |
| B7.d. Animal Models: Optogenetics |
| B7.3. Animal Models: Other |
Theme C: α-Synucleinopathies
| C1.a. Disease Mechanisms, Pathophysiology: Α-synuclein aggregation |
| C1.b. Disease Mechanisms, Pathophysiology: LRKK2, parkin, PINK1, DJ-1 |
| C1.c. Disease Mechanisms, Pathophysiology: Cell to cell transmission, spreading of pathology, prion-like |
| C1.d. Disease Mechanisms, Pathophysiology: Autophagy, lysosomes, ubiquitin, proteasome |
| C1.e. Disease Mechanisms, Pathophysiology: Lipids, lipoproteins and membrane trafficking |
| C1.f. Disease Mechanisms, Pathophysiology: Inflammation |
| C1.g. Disease Mechanisms, Pathophysiology: Microglia |
| C1.h. Disease Mechanisms, Pathophysiology: Astroglia |
| C1.i. Disease Mechanisms, Pathophysiology: Cellular signalling, kinases, phosphatases, calcium |
| C1.i. Disease Mechanisms, Pathophysiology: Mitochondrial dysfunction, oxidative damage |
| C1.j. Disease Mechanisms, Pathophysiology: Vasculature, angiogenesis, blood-brain barrier |
| C1.k. Disease Mechanisms, Pathophysiology: Synapse pathology, neural networks, plasticity, neurogenesis |
| C1.l. Disease Mechanisms, Pathophysiology: Transcriptional & translational regulation, micro RNAs |
| C1.m. Disease Mechanisms, Pathophysiology: apoptosis, cell death |
| C1.n. Disease Mechanisms, Pathophysiology: Protein aggregation, misfolding, chaperones |
| C1.o. Disease Mechanisms, Pathophysiology: Metal ions |
| C1.p. Disease Mechanisms, Pathophysiology: Modeling of disease progression |
| C1.q. Disease Mechanisms, Pathophysiology: Other |
| C2.a. Therapeutic Targets, Mechanisms for Treatment: Α-synuclein |
| C2.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy |
| C2.c. Therapeutic Targets, Mechanisms for Treatment: Kinases, other enzymes |
| C2.d. Therapeutic Targets, Mechanisms for Treatment: Dopamine, neurotransmitters |
| C2.e. Therapeutic Targets, Mechanisms for Treatment: Cell transplantation |
| C2.f. Therapeutic Targets, Mechanisms for Treatment: Deep brain stimulation |
| C2.g. Therapeutic Targets, Mechanisms for Treatment: Anti-inflammatory, anti-oxidant |
| C2.h. Therapeutic Targets, Mechanisms for Treatment: Microglia |
| C2.i. Therapeutic Targets, Mechanisms for Treatment:Astroglia |
| C2.j. Therapeutic Targets, Mechanisms for Treatment: Protein aggregation, misfolding, chaperones |
| C2.k. Therapeutic Targets, Mechanisms for Treatment: Gene therapy and gene editing |
| C2.l. Therapeutic Targets, Mechanisms for Treatment: ASO and RNAi |
| C2.m. Therapeutic Targets, Mechanisms for Treatment: neurogenesis and iPSC |
| C2.n. Therapeutic Targets, Mechanisms for Treatment: Other |
| C3.a. Drug Development, Clinical Trials: Immunotherapy |
| C3.b. Drug Development, Clinical Trials: Vitamins, antioxidants, neuroprotective compounds |
| C3.c. Drug Development, Clinical Trials: Neurotransmitter- and receptor based modulators |
| C3.d. Drug Development, Clinical Trials: Deep brain stimulation |
| C3.e. Drug Development, Clinical Trials: Aggregation inhibitors |
| C3.f. Drug Development, Clinical Trials: Enzyme modulators |
| C3.g. Drug Development, Clinical Trials: Medicinal chemistry approaches, drug repurposing |
| C3.h. Drug Development, Clinical Trials: Drug delivery systems |
| C3.i. Drug Development, Clinical Trials: Non-pharmacological interventions, neurosurgery |
| C3.j. Drug Development, Clinical Trials: Microbiome |
| C3.k. Drug Development, Clinical Trials: Other |
| C4.a. Imaging, Biomarkers, Diagnostics: Structural MRI, MR spectroscopy |
| C4.b. Imaging, Biomarkers, Diagnostics: Functional MRI |
| C4.c. Imaging, Biomarkers, Diagnostics: PET |
| C4.d. Imaging, Biomarkers, Diagnostics: SPECT |
| C4.e. Imaging, Biomarkers, Diagnostics: Multimodal imaging |
| C4.f. Imaging, Biomarkers, Diagnostics: CSF, blood, body fluid biomarkers |
| C4.g. Imaging, Biomarkers, Diagnostics: EEG, brain mapping, MEG |
| C4.h. Imaging, Biomarkers, Diagnostics: Cognitive, psychometric, behavioral and motor tests |
| C4.i. Imaging, Biomarkers, Diagnostics: Microbiome |
| C4.j. Imaging, Biomarkers, Diagnostics: Other |
| C5.a. Genetics, Epidemiology: Whole genome sequencing |
| C5.b. Genetics, Epidemiology: Disease-causing mutations |
| C5.c. Genetics, Epidemiology: GWAS, genetic associations, susceptibility & protective genes |
| C5.d. Genetics, Epidemiology: Aging |
| C5.e. Genetics, Epidemiology: Environmental risk factors |
| C5.f. Genetics, Epidemiology: Inflammation |
| C5.g. Genetics, Epidemiology: Other |
| C6.a. Cell, Molecular and Systems Biology: Α-synuclein |
| C6.b. Cell, Molecular and Systems Biology: LRKK2, parkin, PINK1, DJ-1 and other PD realted genes |
| C6.c. Cell, Molecular and Systems Biology: Growth factors, synaptic plasticity |
| C6.d. Cell, Molecular and Systems Biology: GCPR, dopamine & other receptors |
| C6.e. Cell, Molecular and Systems Biology: Network biology, connectome, protein-protein interations |
| C6.f. Cell, Molecular and Systems Biology: Metabolomics, transcriptomics, lipidomics, proteomics |
| C6.g. Cell, Molecular and Systems Biology: Epigenetics, histone modification, DNA methylation |
| C6.h. Cell, Molecular and Systems Biology: Other |
| C7.a. Animal Models: Transgenic rodents |
| C7.b. Animal Models: Primates, naturally occuring models and brain organoids |
| C7.c. Animal Models: Non-mamalian models |
| C7.d. Animal Models: Optogenetics |
| C7.e. Animal Models: Other |
Theme D: TDP43- and C9orf72-Related Diseases
| D1. Disease Mechanisms, Pathophysiology |
| D2. Therapeutic Targets, Mechanisms for Treatment |
| D3. Drug Development, Clinical Trials |
| D4. Imaging, Biomarkers, Diagnostics |
| D5. Genetics, Epidemiology |
| D6. Cell, Molecular and Systems Biology |
| D7. Animal Models |
Theme E : Vascular Diseases
| E1. Disease Mechanisms, Pathophysiology |
| E2. Therapeutic Targets, Mechanisms for Treatment |
| E3. Drug Development, Clinical Trials |
| E4. Imaging, Biomarkers, Diagnostics |
| E5. Genetics, Epidemiology |
| E6. Cell, Molecular and Systems Biology |
| E7. Animal Models |
Theme F: Prion Diseases
| F1. Disease Mechanisms, Pathophysiology |
| F2. Therapeutic Targets, Mechanisms for Treatment |
| F3. Drug Development, Clinical Trials |
| F4. Imaging, Biomarkers, Diagnostics |
| F5. Genetics, Epidemiology |
| F6. Cell, Molecular and Systems Biology |
| F7. Animal Models |
Theme G: Huntington's and Other Neurodegenerative Diseases
| G1. Disease Mechanisms, Pathophysiology |
| G2. Therapeutic Targets, Mechanisms for Treatment |
| G3. Drug Development, Clinical Trials |
| G4. Imaging, Biomarkers, Diagnostics |
| G5. Genetics, Epidemiology |
| G6. Cell, Molecular and Systems Biology |
| G7. Animal Models |
Theme H: Demyelinating Diseases
| H1. Disease Mechanisms, Pathophysiology |
| H2. Therapeutic Targets, Mechanisms for Treatment |
| H3. Drug Development, Clinical Trials |
| H4. Imaging, Biomarkers, Diagnostics |
| H5. Genetics, Epidemiology |
| H6. Cell, Molecular and Systems Biology |
| H7. Animal Models |
Theme I: Lysosomal Storage Diseases
| I1. Disease Mechanisms, Pathophysiology |
| I2. Therapeutic Targets, Mechanisms for Treatment |
| I3. Drug Development, Clinical Trials |
| I4. Imaging, Biomarkers, Diagnostics |
| I5. Genetics, Epidemiology |
| I6. Cell, Molecular and Systems Biology |
| I7. Animal Models and brain organoids |
Theme J: Psychiatric Symptoms in Neurodegenerative Diseases
| J1. Disease Mechanisms, Pathophysiology |
| J2. Therapeutic Targets, Mechanisms for Treatment |
| J3. Drug Development, Clinical Trials |
| J4. Imaging, Biomarkers, Diagnostics |
| J5. Genetics, Epidemiology |
| J6. Cell, Molecular and Systems Biology |
| J7. Animal Models |
Theme K: Patient Care and Support
| K1.a. Dementia and Cognitive Dyfunction: Caregiver support |
| K1.b. Dementia and Cognitive Dyfunction: Mobile applications, social networks |
| K1.c. Dementia and Cognitive Dyfunction: Cognitive training |
| K1.d. Dementia and Cognitive Dyfunction: Exercise |
| K1.e. Dementia and Cognitive Dyfunction: Support devices & monitoring |
| K1.f. Dementia and Cognitive Dyfunction: Quality of life |
| K1.g. Dementia and Cognitive Dyfunction: Functional foods |
| K1.h. Dementia and Cognitive Dyfunction: Behavioral & psychiatric symptoms |
| K1.i. Dementia and Cognitive Dyfunction: Fall prevention & patient protection |
| K1.j. Dementia and Cognitive Dyfunction: Other |
| K2.a. Movement Disorders: Caregiver support |
| K2.b. Movement Disorders: Mobile applications, social networks |
| K2.c. Movement Disorders: Motor coordination & exercise |
| K2.d. Movement Disorders: Support devices & monitoring |
| K2.e. Movement Disorders: Functional foods |
| K2.f. Movement Disorders: Quality of life |
| K2.g. Movement Disorders: Fall prevention & patient protection |
| K2.g. Movement Disorders: Behavioral & psychiatric symptoms |
| K2.h. Movement Disorders: Other |
Theme L: COVID-19: Impact on Brain Neurodegenerative Diseases
| L1a. Neuropathology of Covid-19 |
| L1b.Neuroimaging of Covid-19 |
| L1c.Neurological manifestations of Covid-19 |
| L1d.Comorbidity of neurodegeneration with Covid-19 |
| L1e.Impact of Covid-19 on clinical trials |
| L1f.CNS invasion of SARS-CoV2 |
| L1g.Epidemiology of Covid-19 in patients with neurodegenerative diseases |